医学临床研究
  2025年4月3日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (7): 1018-1021    DOI: 10.3969/j.issn.1671-7171.2022.07.016
  论著 本期目录 | 过刊浏览 | 高级检索 |
糖尿病性白内障晶状体上皮细胞中MMP-9、ET-1的表达水平及其临床意义
陈宁宁a, 赵铭b*
1.咸阳市第一人民医院:a.眼科; b.玻璃体视网膜外科,陕西 咸阳 712000
Expression and Clinical Significance of MMP-9 and ET-1 in Lens Epithelial Cells of Diabetic Cataract
CHEN Ning-ning, ZHAO Ming
Department of Ophthalmology,Xianyang First People's Hospital,Xianyang Shaanxi 712000
全文: PDF (1848 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨糖尿病性白内障晶状体上皮细胞中基质金属蛋白酶-9(MMP-9)、内皮素-1(ET-1)的表达水平及其临床意义。【方法】选取2019年3月至2021年4月咸阳市第一人民医院眼科收治的131例白内障患者作为观察组,根据患者是否合并糖尿病分为非糖尿病性白内障组(n=31)和糖尿病性白内障组(n=100);另外,选取83例需取出正常透明晶状体的眼部外伤患者作为对照组。采用免疫组织化学法检测各组晶状体上皮细胞中MMP-9、ET-1的表达情况;经Spearman法分析糖尿病性白内障患者晶状体上皮细胞中MMP9、ET-1表达水平与临床指标的相关性;Logistic回归分析糖尿病性白内障的影响因素。【结果】与对照组比较,非糖尿病性白内障组患者晶状体上皮细胞中MMP-9、ET-1阳性表达率明显升高(P<0.05),与非糖尿病性白内障组比较,糖尿病性白内障组患者MMP-9、ET-1阳性表达率升高(P<0.05)。经Spearman法分析结果显示:MMP-9、ET-1表达与空腹血糖(FPG)、总胆固醇(TC)、三酰甘油(TG)、糖化血红蛋白(HbA1c)、超敏C反应蛋白(hs-CRP)、丙二醛(MDA)呈正相关(P<0.05),与高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A(apoA)、超氧化物歧化酶(SOD)、谷胱甘肽(GSH)呈负相关(P<0.05)。多因素logistic回归分析显示:MMP-9、ET-1阳性表达是糖尿病性白内障发生的危险因素(P<0.05)。【结论】糖尿病性白内障患者晶状体上皮细胞中MMP-9、ET-1表达升高,二者与糖尿病性白内障的发生有关。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
陈宁宁
赵铭
关键词 糖尿病/并发症白内障/并发症晶体上皮细胞基质金属蛋白酶9内皮缩血管肽1    
Abstract:【Objective】 To investigate the expression and clinical significance of matrix metalloproteinase-9 (MMP-9) and endothelin-1 (ET-1) in diabetic cataract lens epithelial cells. 【Methods】From March 2019 to April 2021, 131 cataract patients accepted in the ophthalmology department of Xianyang First People's Hospital were collected as the research group. According to whether the patients were complicated with diabetes, they were divided into the non-diabetic cataract group of 31 cases and the diabetic cataract group of 100 cases. In addition, 83 cases of ocular trauma requiring removal of the normal transparent lens due to trauma accident were recruited as the control group. The expression of MMP-9 and ET-1 was detected by immunohistochemistry. The correlation of MMP-9 and ET-1 expression in lens epithelial cells of patients with diabetic cataract clinical indicators was analyzed by Spearman method. The related factors affecting diabetic cataract were analyzed by Logistic regression. 【Results】Compared with the control group, the positive expression of MMP-9 and ET-1 in the lens epithelial cells of the non-diabetic cataract group was obviously increased (P<0.05); compared with the non-diabetic cataract group, the positive expression of MMP-9 and ET-1 in the diabetic cataract group was increased (P<0.05). The results of Spearman analysis showed that the expression of MMP-9 and ET-1 was positively associated with fasting blood glucose (FPG), total cholesterol (TC), triglyceride (TG), hemoglobin A1C (HbA1c), high sensitive C-reactive protein (hs-CRP) and malondialdehyde (MDA) (P<0.05), and they were negatively correlated with high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (apoA), superoxide dismutase (SOD) and glutathione (GSH) (P<0.05). Multivariate logistic regression analysis showed that the positive expression of MMP-9 and ET-1 were risk factors for the occurrence of diabetic cataract (P<0.05). 【Conclusion】The expression of MMP-9 and ET-1 in lens epithelial cells of patients with diabetic cataract is increased, which are related to the occurrence of diabetic cataract.
Key wordsDiabetes Mellitus/CO    Cataract/CO    Lens, Crystalline    Epithelial Cells    Matrix Metalloproteinase 9    Endothelin-1
收稿日期: 2022-03-08     
中图分类号:  R776.1  
通讯作者: *E-mail:xiangyi2080@163.com   
引用本文:   
陈宁宁, 赵铭. 糖尿病性白内障晶状体上皮细胞中MMP-9、ET-1的表达水平及其临床意义[J]. 医学临床研究, 2022, 39(7): 1018-1021.
CHEN Ning-ning, ZHAO Ming. Expression and Clinical Significance of MMP-9 and ET-1 in Lens Epithelial Cells of Diabetic Cataract. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1018-1021.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.016     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/1018
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn